Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
MedPlus Health Services informed stock exchanges that its subsidiary, Optival Health Solutions Private Limited, received two suspension orders for drug licenses. The first is a 7-day suspension for a store in Purasaiwalkam Tana Street, Chennai, with a potential revenue loss of about Rs 1.19 lakhs. The second is a 3-day suspension for a store in Shanthi Nagar, Shikaripura, Karnataka, with a potential revenue loss of about Rs 0.68 lakhs. Both orders were issued by Assistant Directors of Drugs Control Administration and received on May 12, 2025, under Rule 65 of the Drugs and Cosmetics Act, 1940. The combined financial impact is roughly Rs 1.87 lakhs.
The financial impact is negligible (under Rs 2 lakhs combined) and limited to two single stores, so this is unlikely to materially affect MedPlus's operations, earnings, or stock price. It is a routine regulatory compliance disclosure rather than a significant business event.